Bio‐Assisted Synthesis of Reduced Graphene Oxide Nanosheets From Graphene Oxide: Promising and Efficient Cytotoxic and Antidiabetic Potency in In Vitro, Kinetic, and In Silico Models
Abstract
Green chemistry has recently made strides in the sustainable synthesis of next‐generation nanomaterials using reducing agents sourced from plants. Biocompatible conversion of reduced graphene oxide from graphene oxide nanomaterials is of particular interest in medical applications. The leaf extract of C. igneus functions as a reducing agent to produce reduced graphene oxide nanosheets from its precursor graphene oxide. A variety of characterization techniques were employed to confirm the formation and stability of reduced graphene oxide nanosheets. The cytotoxicity and glucose uptake potential of nanosheets have been evaluated through in vitro cell‐based assays. The MTT assay revealed a concentration‐dependent cytotoxic effect on Chang liver and U87MG cells, with maximum 84.5% and 76.3% cell viability, respectively. Reduced graphene oxide exhibited a significant rise in glucose uptake, comparable to the metformin drug, with increasing concentration. Enhanced glucose transport mediated by the nanosheets resulted in increased glucose uptake. Effective IC50 values of 84.46 μg·mL−1 and 93.83 μg·mL−1 were obtained in vitro enzyme inhibition studies against α‐amylase and α‐glucosidase, respectively. The enzyme kinetic investigation found noncompetitive inhibition for both enzymes. Molecular docking studies of C. igneus leaf derivatives were performed against α‐amylase and α‐glucosidase. Corosolic acid was selected based on favorable docking scores, binding interactions, and low…
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in cell cultures (in vitro) and computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.